These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 11196162)

  • 1. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
    Ferrara FF; Fazi F; Bianchini A; Padula F; Gelmetti V; Minucci S; Mancini M; Pelicci PG; Lo Coco F; Nervi C
    Cancer Res; 2001 Jan; 61(1):2-7. PubMed ID: 11196162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?
    Minucci S; Nervi C; Lo Coco F; Pelicci PG
    Oncogene; 2001 May; 20(24):3110-5. PubMed ID: 11420727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.
    Moldenhauer A; Frank RC; Pinilla-Ibarz J; Holland G; Boccuni P; Scheinberg DA; Salama A; Seeger K; Moore MA; Nimer SD
    J Leukoc Biol; 2004 Sep; 76(3):623-33. PubMed ID: 15197237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
    Qi H; Ratnam M
    Cancer Res; 2006 Jun; 66(11):5875-82. PubMed ID: 16740727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
    Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M
    Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts.
    Gozzini A; Rovida E; Dello Sbarba P; Galimberti S; Santini V
    Cancer Res; 2003 Dec; 63(24):8955-61. PubMed ID: 14695213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
    Wang J; Saunthararajah Y; Redner RL; Liu JM
    Cancer Res; 1999 Jun; 59(12):2766-9. PubMed ID: 10383127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting aberrant transcriptional repression in acute myeloid leukemia.
    Moe-Behrens GH; Pandolfi PP
    Rev Clin Exp Hematol; 2003 Jun; 7(2):139-59. PubMed ID: 14763160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
    Savickiene J; Treigyte G; Magnusson KE; Navakauskiene R
    Ann N Y Acad Sci; 2009 Aug; 1171():321-33. PubMed ID: 19723072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
    Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
    Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
    Fliegauf M; Stock M; Berg T; Lübbert M
    Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
    Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
    Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.
    Barbetti V; Gozzini A; Rovida E; Morandi A; Spinelli E; Fossati G; Mascagni P; Lübbert M; Dello Sbarba P; Santini V
    Oncogene; 2008 Mar; 27(12):1767-78. PubMed ID: 17891169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
    Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G
    Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells.
    Cras A; Darsin-Bettinger D; Balitrand N; Cassinat B; Soulié A; Toubert ME; Delva L; Chomienne C
    Oncogene; 2007 Jun; 26(27):4018-24. PubMed ID: 17213810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
    Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
    Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia.
    Fazi F; Zardo G; Gelmetti V; Travaglini L; Ciolfi A; Di Croce L; Rosa A; Bozzoni I; Grignani F; Lo-Coco F; Pelicci PG; Nervi C
    Blood; 2007 May; 109(10):4432-40. PubMed ID: 17244680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
    Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
    Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo.
    Fazi F; Travaglini L; Carotti D; Palitti F; Diverio D; Alcalay M; McNamara S; Miller WH; Lo Coco F; Pelicci PG; Nervi C
    Oncogene; 2005 Mar; 24(11):1820-30. PubMed ID: 15688037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.